{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:32:04Z","timestamp":1791304324540,"version":"4.3.1"},"reference-count":47,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["2015R1C1A2A01055073"],"award-info":[{"award-number":["2015R1C1A2A01055073"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["2016M3D1A1021387"],"award-info":[{"award-number":["2016M3D1A1021387"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004085","name":"Ministry of Education, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004085","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.jid.2017.11.012","type":"journal-article","created":{"date-parts":[[2017,11,24]],"date-time":"2017-11-24T08:17:13Z","timestamp":1511511433000},"page":"768-774","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"title":["Increased Risk of Vitiligo Following Anti-Tumor Necrosis Factor Therapy: A 10-Year Population-Based Cohort Study"],"prefix":"10.1016","volume":"138","author":[{"given":"Jung Min","family":"Bae","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miri","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki-Jo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyoseung","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Jeong","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyong Moon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul Jong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Jeong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2017.11.012_bib1","first-page":"534","article-title":"Treatment of generalized vitiligo with anti-TNF-alpha Agents","volume":"11","author":"Alghamdi","year":"2012","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.jid.2017.11.012_bib2","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00403-012-1269-6","article-title":"Over-expression of tumor necrosis factor-alpha in vitiligo lesions after narrow-band UVB therapy: an immunohistochemical study","volume":"304","author":"Attwa","year":"2012","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jid.2017.11.012_bib3","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.jaad.2016.12.034","article-title":"Vitiligo and overt thyroid diseases: a nationwide population-based study in Korea","volume":"76","author":"Bae","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2017.11.012_bib4","article-title":"Factors affecting the quality of life in patients with vitiligo: a nationwide study","author":"Bae","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2017.11.012_bib5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.5070\/D331C9H7FX","article-title":"Alopecia areata universalis during off-label treatment with Infliximab in a patient with Behcet disease","volume":"16","author":"Beccastrini","year":"2010","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.jid.2017.11.012_bib6","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1136\/annrheumdis-2014-205322","article-title":"Efficacy of TNFalpha blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis","volume":"74","author":"Callhoff","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jid.2017.11.012_bib7","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1590\/abd1806-4841.20142887","article-title":"Segmental vitiligo after infliximab use for rheumatoid arthritis\u2014a case report","volume":"89","author":"Carvalho","year":"2014","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.jid.2017.11.012_bib8","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1007\/s00296-013-2833-x","article-title":"Development of an algorithm for identifying rheumatoid arthritis in the Korean National Health Insurance claims database","volume":"33","author":"Cho","year":"2013","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jid.2017.11.012_bib9","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/1346-8138.13846","article-title":"Increased risk of comorbid rheumatic disorders in vitiligo patients: a nationwide population-based study","volume":"44","author":"Choi","year":"2017","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jid.2017.11.012_bib10","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamadermatol.2015.1520","article-title":"Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapy","volume":"151","author":"Craiglow","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2017.11.012_bib11","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1001\/archderm.140.8.1012-a","article-title":"Alopecia areata in a patient using infliximab: new insights into the role of tumor necrosis factor on human hair follicles","volume":"140","author":"Ettefagh","year":"2004","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jid.2017.11.012_bib12","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1080\/03009740902922612","article-title":"Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors","volume":"38","author":"Exarchou","year":"2009","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.jid.2017.11.012_bib13","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1468-3083.2010.03770.x","article-title":"Alopecia areata as another immune-mediated disease developed in patients treated with tumour necrosis factor-alpha blocker agents: report of five cases and review of the literature","volume":"25","author":"Ferran","year":"2011","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2017.11.012_bib14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.autrev.2013.06.005","article-title":"Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-alpha agents","volume":"13","author":"Fiorino","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jid.2017.11.012_bib15","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1001\/archderm.142.12.1654","article-title":"Development of alopecia areata universalis in a patient receiving adalimumab","volume":"142","author":"Garcia Bartels","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jid.2017.11.012_bib16","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/jid.2011.463","article-title":"A\u00a0mouse model of vitiligo with focused epidermal depigmentation requires IFN-gamma for autoreactive CD8(+) T-cell accumulation in the skin","volume":"132","author":"Harris","year":"2012","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2017.11.012_bib17","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jaad.2015.09.073","article-title":"Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)","volume":"74","author":"Harris","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2017.11.012_bib18","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/ard.2007.087288","article-title":"Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register","volume":"68","author":"Harrison","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jid.2017.11.012_bib19","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ajg.2011.03.001","article-title":"Vitiligo in a patient receiving infliximab for refractory ulcerative colitis","volume":"12","author":"Ismail","year":"2011","journal-title":"Arab J Gastroenterol"},{"key":"10.1016\/j.jid.2017.11.012_bib20","first-page":"295","article-title":"Prevalence of systemic lupus erythematosus in South Korea: an administrative database study","volume":"24","author":"Ju","year":"2014","journal-title":"J\u00a0Epidemiol"},{"key":"10.1016\/j.jid.2017.11.012_bib21","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2016.08.022","article-title":"Inflammatory bowel disease is associated with an increased risk of inflammatory skin diseases: a population-based cross-sectional study","volume":"76","author":"Kim","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2017.11.012_bib22","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3109\/15569527.2011.560913","article-title":"Tumor necrosis factor-alpha in vitiligo: direct correlation between tissue levels and clinical parameters","volume":"30","author":"Kim","year":"2011","journal-title":"Cutan Ocul Toxicol"},{"key":"10.1016\/j.jid.2017.11.012_bib23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/heapol\/czn037","article-title":"Thirty years of national health insurance in South Korea: lessons for achieving universal health care coverage","volume":"24","author":"Kwon","year":"2009","journal-title":"Health Policy Plan"},{"key":"10.1016\/j.jid.2017.11.012_bib24","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3899\/jrheum.100968","article-title":"Vasculitis, vitiligo, thyroiditis, and altered hormone levels after anti-tumor necrosis factor therapy","volume":"38","author":"Lahita","year":"2011","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.jid.2017.11.012_bib25","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.annder.2011.01.047","article-title":"[Alopecia areata during anti-TNF alpha therapy: Nine cases]","volume":"138","author":"Le Bidre","year":"2011","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.jid.2017.11.012_bib26","doi-asserted-by":"crossref","first-page":"719","DOI":"10.3349\/ymj.2015.56.3.719","article-title":"Prevalence of vitiligo and associated comorbidities in Korea","volume":"56","author":"Lee","year":"2015","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.jid.2017.11.012_bib27","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.clim.2007.08.012","article-title":"TNFalpha blockade in human diseases: an overview of efficacy and safety","volume":"126","author":"Lin","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jid.2017.11.012_bib28","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/art.27203","article-title":"Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells","volume":"62","author":"Ma","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jid.2017.11.012_bib29","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/dth.12002","article-title":"Deterioration of vitiligo and new onset of halo naevi observed in two patients receiving adalimumab","volume":"26","author":"Maruthappu","year":"2013","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jid.2017.11.012_bib30","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.semarthrit.2008.11.003","article-title":"Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new \u201cclass effect\u201d paradoxical phenomenon. Two case reports and literature review","volume":"39","author":"Massara","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jid.2017.11.012_bib31","first-page":"217","article-title":"New-onset vitiligo during long-term, stable infliximab treatment of pityriasis rubra pilaris","volume":"12","author":"Mattox","year":"2013","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.jid.2017.11.012_bib32","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/jid.2013.464","article-title":"Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990\u22122009","volume":"134","author":"Mirzoyev","year":"2014","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2017.11.012_bib33","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1001\/archderm.138.2.273","article-title":"Vitiligo and epidermal microenvironment: possible involvement of keratinocyte-derived cytokines","volume":"138","author":"Moretti","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jid.2017.11.012_bib34","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1034\/j.1600-0749.2002.1o049.x","article-title":"New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions","volume":"15","author":"Moretti","year":"2002","journal-title":"Pigment Cell Res"},{"key":"10.1016\/j.jid.2017.11.012_bib35","first-page":"313","article-title":"Association between vitiligo and spondyloarthritis","volume":"28","author":"Padula","year":"2001","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.jid.2017.11.012_bib36","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1073\/pnas.0408506102","article-title":"Cross-regulation of TNF and IFN-alpha in autoimmune diseases","volume":"102","author":"Palucka","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jid.2017.11.012_bib37","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000324619","article-title":"Vitiligo during treatment of Crohn\u2019s disease with adalimumab: adverse effect or co-occurrence?","volume":"3","author":"Posada","year":"2011","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.jid.2017.11.012_bib38","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/apt.13352","article-title":"Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study","volume":"42","author":"Pugliese","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jid.2017.11.012_bib39","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000081494","article-title":"Infliximab-induced vitiligo","volume":"210","author":"Ramirez-Hernandez","year":"2005","journal-title":"Dermatology"},{"key":"10.1016\/j.jid.2017.11.012_bib40","doi-asserted-by":"crossref","first-page":"223ra23","DOI":"10.1126\/scitranslmed.3007811","article-title":"CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo","volume":"6","author":"Rashighi","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jid.2017.11.012_bib41","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000102044","article-title":"Etanercept in the treatment of vitiligo","volume":"215","author":"Rigopoulos","year":"2007","journal-title":"Dermatology"},{"key":"10.1016\/j.jid.2017.11.012_bib42","doi-asserted-by":"crossref","first-page":"817","DOI":"10.2217\/imt.10.67","article-title":"Anti-TNF-alpha agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls","volume":"2","author":"Silva","year":"2010","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jid.2017.11.012_bib43","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1159\/000112932","article-title":"Vitiligo improvement in a patient with ankylosing spondylitis treated with infliximab","volume":"216","author":"Simon","year":"2008","journal-title":"Dermatology"},{"issue":"Suppl. 1","key":"10.1016\/j.jid.2017.11.012_bib44","doi-asserted-by":"crossref","first-page":"i46","DOI":"10.1136\/ard.59.suppl_1.i46","article-title":"Etanercept (Enbrel): update on therapeutic use","volume":"59","author":"Spencer-Green","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jid.2017.11.012_bib45","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/labinvest.3780138","article-title":"Local immune response in skin of generalized vitiligo patients. Destruction of melanocytes is associated with the prominent presence of CLA+ T cells at the perilesional site","volume":"80","author":"van den Wijngaard","year":"2000","journal-title":"Lab Invest"},{"key":"10.1016\/j.jid.2017.11.012_bib46","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/ecco-jcc\/jjv193","article-title":"Inflammatory bowel disease and the risk of autoimmune diseases","volume":"10","author":"Wilson","year":"2016","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.jid.2017.11.012_bib47","first-page":"450","article-title":"Alopecia areata during treatment with adalimumab: therapy with an alternative TNF-alpha inhibitor is possible","volume":"11","author":"Zschoche","year":"2013","journal-title":"J\u00a0Dtsch Dermatol Ges"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X17331676?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X17331676?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T08:33:13Z","timestamp":1659947593000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X17331676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0022202X17331676"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2017.11.012","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increased Risk of Vitiligo Following Anti-Tumor Necrosis Factor Therapy: A 10-Year Population-Based Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2017.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}